Search

Your search keyword '"Thouvenot, Eric"' showing total 627 results
Start Over Author "Thouvenot, Eric"
627 results on '"Thouvenot, Eric"'

2. The diagnostic workup of children with the radiologically isolated syndrome differs by age and by sex

Author

Makhani, Naila, Lebrun-Frenay, Christine, Siva, Aksel, Shabanova, Veronika, Wassmer, Evangeline, Santoro, Jonathan D., Narula, Sona, Brenton, J. Nicholas, Mar, Soe, Durand-Dubief, Francoise, Zephir, Helene, Mathey, Guillaume, Rojas, Juan I., de Seze, Jerome, Tenembaum, Silvia, Stone, Robert Thompson, Casez, Olivier, Carra-Dallière, Clarisse, Neuteboom, Rinze F., Ahsan, Nusrat, Arroyo, Hugo A., Cabre, Philippe, Gombolay, Grace, Inglese, Matilde, Louapre, Celine, Margoni, Monica, Palavra, Filipe, Pohl, Daniela, Reich, Daniel S., Ruet, Aurélie, Thouvenot, Eric, Timby, Niklas, Tintore, Mar, Uygunoglu, Ugur, Vargas, Wendy, Venkateswaran, Sunita, Verhelst, Helene, Wickstrom, Ronny, Azevedo, Christina J., Kantarci, Orhun, Shapiro, Eugene D., Okuda, Darin T., and Pelletier, Daniel

Published
2024
Full Text
View/download PDF

3. Primary acute convexity subarachnoid hemorrhage in older patients: analysis of baseline, clinical and MRI characteristics including quantitative surface study and topographical probabilistic mapping of convexity subarachnoid hemorrhage

Author

Autieri, Vincenzo, Gaillard, Nicolas, Mourand, Isabelle, Laurent-Chabalier, Sabine, Mura, Thibault, Trandafir, Cassiana, Wacongne, Anne, de Champfleur, Nicolas Menjot, Thouvenot, Eric, Pereira, Fabricio, and Renard, Dimitri

Published
2023
Full Text
View/download PDF

8. Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal

Author

Rollot, Fabien, Couturier, Justine, Casey, Romain, Wiertlewski, Sandrine, Debouverie, Marc, Pelletier, Jean, De Sèze, Jérôme, Labauge, Pierre, Ruet, Aurélie, Thouvenot, Eric, Ciron, Jonathan, Berger, Eric, Gout, Olivier, Clavelou, Pierre, Stankoff, Bruno, Casez, Olivier, Bourre, Bertrand, Zephir, Hélène, Moreau, Thibault, Lebrun-Frenay, Christine, Maillart, Elisabeth, Edan, Gilles, Neau, Jean-Philippe, Montcuquet, Alexis, Cabre, Philippe, Camdessanché, Jean-Philippe, Defer, Gilles, Nasr, Haifa Ben, Maurousset, Aude, Hankiewicz, Karolina, Pottier, Corinne, Leray, Emmanuelle, Vukusic, Sandra, and Laplaud, David-Axel

Published
2022
Full Text
View/download PDF

9. Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference

Author

Gavoille, Antoine, Rollot, Fabien, Casey, Romain, Debouverie, Marc, Le Page, Emmanuelle, Ciron, Jonathan, De Seze, Jerome, Ruet, Aurélie, Maillart, Elisabeth, Labauge, Pierre, Zephir, Helene, Papeix, Caroline, Defer, Gilles, Lebrun-Frenay, Christine, Moreau, Thibault, Laplaud, David Axel, Berger, Eric, Stankoff, Bruno, Clavelou, Pierre, Thouvenot, Eric, Heinzlef, Olivier, Pelletier, Jean, Al Khedr, Abdullatif, Casez, Olivier, Bourre, Bertrand, Cabre, Philippe, Wahab, Abir, Magy, Laurent, Camdessanche, Jean-Philippe, Maurousset, Aude, Moulin, Solène, Ben, Nasr Haifa, Boulos, Dalia Dimitri, Hankiewicz, Karolina, Neau, Jean-Philippe, Pottier, Corinne, Nifle, Chantal, Rabilloud, Muriel, Subtil, Fabien, and Vukusic, Sandra

Published
2022
Full Text
View/download PDF

10. Choroid plexus enlargement correlates with periventricular pathology but not with disease activity in radiologically isolated syndrome.

Author

Landes-Château, Cassandre, Ricigliano, Vito AG, Mondot, Lydiane, Thouvenot, Eric, Labauge, Pierre, Louapre, Céline, Zéphir, Hélène, Durand-Dubief, Françoise, Le Page, Emmanuelle, Siva, Aksel, Cohen, Mikael, Yazdan Panah, Arya, Azevedo, Christina J., Okuda, Darin T., Stankoff, Bruno, and Lebrun-Frénay, Christine

Subjects
CHOROID plexus, BIOMARKERS, BRAIN damage, MULTIPLE sclerosis, PATHOLOGY
Abstract

Background: Choroid plexus (ChP) enlargement is an emerging radiological biomarker in multiple sclerosis (MS). Objectives: This study aims to assess ChP volume in a large cohort of patients with radiologically isolated syndrome (RIS) versus healthy controls (HC) and explore its relationship with other brain volumes, disease activity, and biological markers. Methods: RIS individuals were included retrospectively and compared with HC. ChPs were automatically segmented using an in-house automated algorithm and manually corrected. Results: A total of 124 patients fulfilled the 2023 RIS criteria, and 55 HCs were included. We confirmed that ChPs are enlarged in RIS versus HC (mean (±SD) normalized ChP volume: 17.24 (±4.95) and 11.61 (±3.58), respectively, p < 0.001). Larger ChPs were associated with more periventricular lesions (ρ = 0.26; r 2 = 0.27; p = 0.005 for the correlation with lesion volume, and ρ = 0.2; r 2 = 0.21; p = 0.002 for the correlation with lesion number) and lower thalamic volume (ρ = −0.38; r 2 = 0.44; p < 0.001), but not with lesions in other brain regions. Conversely, ChP volume did not correlate with biological markers. No significant difference in ChP volume was observed between subjects who presented or did not have a clinical event or between those with or without imaging disease activity. Conclusions: This study provides evidence that ChP volume is higher in RIS and is associated with measures reflecting periventricular pathology but does not correlate with biological, radiological, or clinical markers of disease activity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. CD138 as a Specific CSF Biomarker of Multiple Sclerosis

Author

Hinsinger, Geoffrey, primary, Du Trieu De Terdonck, Lucile, additional, Urbach, Serge, additional, Salvetat, Nicolas, additional, Rival, Manon, additional, Galoppin, Manon, additional, Ripoll, Chantal, additional, Cezar, Renaud, additional, Laurent-Chabalier, Sabine, additional, Demattei, Christophe, additional, Agherbi, Hanane, additional, Castelnovo, Giovanni, additional, Lehmann, Sylvain, additional, Rigau, Valérie, additional, Marin, Philippe, additional, and Thouvenot, Eric, additional

Published
2024
Full Text
View/download PDF

14. Prognostic Value of Serum Neurofilament Light Chain for Disease Activity in Patients with Relapsing Multiple Sclerosis: Results from Subgroup Analysis Based on Body Mass Index and Age from the Phase 3 ASCLEPIOS I/II Trials (P6-6.011)

Author

Cross, Anne, primary, Ziemssen, Tjalf, additional, Arnold, Douglas, additional, Thouvenot, Eric, additional, Zamvil, Scott, additional, Bhatt, Alit, additional, Wei, Wenjia, additional, Boer, Ibolya, additional, Alvarez, Enrique, additional, and Wiendl, Heinz, additional

Published
2024
Full Text
View/download PDF

15. Performance of the 2023 Adult Criteria for the Radiologically Isolated Syndrome in Children and Comparison to the 2009 Criteria (P4-6.007)

Author

Makhani, Naila, primary, Frenay, Christine Lebrun, additional, Siva, Aksel, additional, Shabanova, Veronika, additional, Wassmer, Evangeline, additional, Santoro, Jonathan, additional, Narula, Sona, additional, Brenton, James, additional, Mar, Soe, additional, Dubief, Francoise Durand, additional, Zephir, Helene, additional, Mathey, Guillaume, additional, Rojas, Juan Ignacio, additional, De Seze, Jerome, additional, Tenembaum, Silvia, additional, Thompson-Stone, Robert, additional, Casez, Olivier, additional, Carra-Dalliere, Clarisse, additional, Neuteboom, Rinze F., additional, Ahsan, Nusrat, additional, Arroyo, Hugo, additional, Cabre, Philippe, additional, Gombolay, Grace, additional, Inglese, Matilde, additional, Louapre, Celine, additional, Margoni, Monica, additional, Palavra, Filipe, additional, Pohl, Daniela, additional, Reich, Daniel, additional, Ruet, Aurelie, additional, Thouvenot, Eric, additional, Timby, Niklas, additional, Tintore, Mar, additional, Uygunoglu, Ugur, additional, Vargas, Wendy, additional, Verhelst, Helene, additional, Wickstrom, Ronny, additional, Azevedo, Christina, additional, Kantarci, Orhun, additional, Shapiro, Eugene, additional, Okuda, Darin, additional, and Pelletier, Daniel, additional

Published
2024
Full Text
View/download PDF

17. Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study

Author

Levraut, Michael, Laurent-Chabalier, Sabine, Ayrignac, Xavier, Bigaut, Kévin, Rival, Manon, Squalli, Sanae, Zéphir, Hélène, Alberto, Tifanie, Pekar, Jean-David, Ciron, Jonathan, Biotti, Damien, Puissant-Lubrano, Bénédicte, Camdessanché, Jean-Philippe, Tholance, Yannick, Casez, Olivier, Toussaint, Bertrand, Marion, Jeanne, Moreau, Thibault, Lakomy, Daniela, Thomasset, Audrey, Maillart, Elisabeth, Sterlin, Delphine, Maurousset, Aude, Rocher, Auriane, Laplaud, David Axel, Bigot-Corbel, Edith, Bertho, Pierre-Olivier, Pelletier, Jean, Boucraut, Joseph, Labauge, Pierre, Vincent, Thierry, De Sèze, Jérôme, Jahn, Isabelle, Seitz-Polski, Barbara, Thouvenot, Eric, and Lebrun-Frenay, Christine

Published
2023
Full Text
View/download PDF

19. Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations

Author

Deschamps, Romain, Papeix, Caroline, Ayrignac, Xavier, Bourre, Bertrand, Ciron, Jonathan, Cohen, Mikael, Collongues, Nicolas, Deiva, Kumaran, Durand Dubief, Françoise, Laplaud, David-Axel, Maillart, Elisabeth, Michel, Laure, Pique, Julie, Ruet, Aurélie, Thouvenot, Eric, Zéphir, Hélène, Marignier, Romain, and Audoin, Bertrand

Published
2024
Full Text
View/download PDF

21. Early Maintenance Treatment Initiation and Relapse Risk Mitigation After a First Event of MOGADin Adults: The MOGADOR2 Study.

Author

Deschamps, Romain, Guillaume, Jessica, Ciron, Jonathan, Audoin, Bertrand, Ruet, Aurélie, Maillart, Elisabeth, Pique, Julie, Benyahya, Lakhdar, Laplaud, David A., Michel, Laure, Collongues, Nicolas, Cohen, Mikael, Ayrignac, Xavier, Thouvenot, Eric, Zephir, Helene, Bourre, Bertrand, Froment Tilikete, Caroline, Moreau, Thibault, Cantagrel, Paul, and Kerschen, Philippe

Published
2024
Full Text
View/download PDF

23. Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society.

Author

Collongues, Nicolas, Durand-Dubief, Françoise, Lebrun-Frenay, Christine, Audoin, Bertrand, Ayrignac, Xavier, Bensa, Caroline, Bigaut, Kévin, Bourre, Bertrand, Carra-Dallière, Clarisse, Ciron, Jonathan, Defer, Gilles, Kwiatkowski, Arnaud, Leray, Emmanuelle, Maillart, Elisabeth, Marignier, Romain, Mathey, Guillaume, Morel, Nathalie, Thouvenot, Eric, Zéphir, Hélène, and Boucher, Julie

Subjects
MULTIPLE sclerosis, DISEASE risk factors, MEDICAL care, EARLY detection of cancer, IMMUNOSUPPRESSIVE agents
Abstract

Background: Epidemiological data reveal that 45% of persons with multiple sclerosis (PwMS) in France are more than 50 years. This population more than 50 is more susceptible to cancer, and this risk may be increased by frequent use of immunosuppressive drugs. Consequently, concerns have arisen about the potential increased risk of cancer in PwMS and how patients should be screened and managed in terms of cancer risk. Objective: To develop evidence-based recommendations to manage the coexistence of cancer and multiple sclerosis (MS). Methods: The French Group for Recommendations in MS collected articles from PubMed and university databases covering the period January 1975 through June 2022. The RAND/UCLA method was employed to achieve formal consensus. MS experts comprehensively reviewed the full-text articles and developed the initial recommendations. A group of multidisciplinary health care specialists then validated the final proposal. Results: Five key questions were addressed, encompassing various topics such as cancer screening before or after initiating a disease-modifying therapy (DMT), appropriate management of MS in the context of cancer, recommended follow-up for cancer in patients receiving a DMT, and the potential reintroduction of a DMT after initial cancer treatment. A strong consensus was reached for all 31 recommendations. Conclusion: These recommendations propose a strategic approach to managing cancer risk in PwMS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022

Author

Jeantin, Lina, primary, Januel, Edouard, additional, Labauge, Pierre, additional, Maillart, Elisabeth, additional, de Seze, Jérôme, additional, Zéphir, Hélène, additional, Pelletier, Jean, additional, Kerschen, Philippe, additional, Biotti, Damien, additional, Heinzlef, Olivier, additional, Guilloton, Laurent, additional, Bensa, Caroline, additional, Théaudin, Marie, additional, Vukusic, Sandra, additional, Casez, Olivier, additional, Maurousset, Aude, additional, Laplaud, David, additional, Berger, Eric, additional, Lebrun-Frenay, Christine, additional, Bourre, Bertrand, additional, Branger, Pierre, additional, Stankoff, Bruno, additional, Clavelou, Pierre, additional, Thouvenot, Eric, additional, Manchon, Eric, additional, Moreau, Thibault, additional, Sellal, François, additional, Zedet, Mickaël, additional, Papeix, Caroline, additional, and Louapre, Céline, additional

Published
2024
Full Text
View/download PDF

26. Comparison of 2 Methods for Estimating Multiple Sclerosis–Related Mortality

Author

Rollot, Fabien, primary, Uhry, Zoé, additional, Dantony, Emmanuelle, additional, Vukusic, Sandra, additional, Debouverie, Marc, additional, Le Page, Emmanuelle, additional, Ciron, Jonathan, additional, Ruet, Aurélie, additional, De Sèze, Jérome, additional, Zéphir, Hélène, additional, Labauge, Pierre, additional, Defer, Gilles, additional, Lebrun-Frenay, Christine, additional, Moreau, Thibault, additional, Laplaud, David A., additional, Berger, Eric, additional, Clavelou, Pierre, additional, Pelletier, Jean, additional, Thouvenot, Eric, additional, Heinzlef, Olivier, additional, Camdessanche, Jean-Philippe, additional, Fauvernier, Mathieu, additional, Remontet, Laurent, additional, and Leray, Emmanuelle, additional

Published
2023
Full Text
View/download PDF

27. One-month humoral response following two or three doses of messenger RNA coronavirus disease 2019 vaccines as primary vaccination in specific populations in France: first results from the Agence Nationale Recherche contre le Sida (ANRS)0001S COV-POPART cohort

Author

Loubet, Paul, Wittkop, Linda, Ninove, Laetitia, Chalouni, Mathieu, Barrou, Benoit, Blay, Jean-Yves, Hourmant, Maryvonne, Thouvenot, Eric, Laville, Martine, Laviolle, Bruno, Lelievre, Jean-Daniel, Morel, Jacques, Quoc, Stéphanie Nguyen, Spano, Jean-Philippe, Terrier, Benjamin, Thiebaut, Anne, Viallard, Jean-Francois, Vrtovsnik, François, Circosta, Sophie, Esterle, Laure, Levier, Axel, Vanhems, Philippe, Tartour, Eric, Parfait, Beatrice, de Lamballerie, Xavier, and Launay, Odile

Published
2023
Full Text
View/download PDF

29. Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis

Author

Gavoille, Antoine, Rollot, Fabien, Casey, Romain, Kerbrat, Anne, Le Page, Emmanuelle, Bigaut, Kevin, Mathey, Guillaume, Michel, Laure, Ciron, Jonathan, Ruet, Aurelie, Maillart, Elisabeth, Labauge, Pierre, Zephir, Hélène, Papeix, Caroline, Defer, Gilles, Lebrun-Frenay, Christine, Moreau, Thibault, Berger, Eric, Stankoff, Bruno, Clavelou, Pierre, Thouvenot, Eric, Heinzlef, Olivier, Pelletier, Jean, Al-Khedr, Abdullatif, Casez, Olivier, Bourre, Bertrand, Cabre, Philippe, Wahab, Abir, Magy, Laurent, Camdessanché, Jean-Philippe, Doghri, Inès, Moulin, Solène, Ben-Nasr, Haifa, Labeyrie, Céline, Hankiewicz, Karolina, Neau, Jean-Philippe, Pottier, Corinne, Nifle, Chantal, Manchon, Eric, Lapergue, Bertrand, Wiertlewski, Sandrine, De Sèze, Jérôme, Vukusic, Sandra, and Laplaud, David Axel

Abstract

IMPORTANCE: Understanding the association between clinically defined relapses and radiological activity in multiple sclerosis (MS) is essential for patient treatment and therapeutic development. OBJECTIVE: To investigate clinical events identified as relapses but not associated with new T2 lesions or gadolinium-enhanced T1 lesions on brain and spinal cord magnetic resonance imaging (MRI). DESIGN, SETTING, AND PARTICIPANTS: This multicenter observational cohort study was conducted between January 2015 and June 2023. Data were extracted on June 8, 2023, from the French MS registry. All clinical events reported as relapses in patients with relapsing-remitting MS were included if brain and spinal cord MRI was performed within 12 and 24 months before the event, respectively, and 50 days thereafter with gadolinium injection. EXPOSURES: Events were classified as relapses with active MRI (RAM) if a new T2 lesion or gadolinium-enhanced T1 lesion appeared on brain or spinal cord MRI or as acute clinical events with stable MRI (ACES) otherwise. MAIN OUTCOMES AND MEASURES: Factors associated with ACES were investigated; patients with ACES and RAM were compared regarding Expanded Disability Status Scale (EDSS) course, relapse rate, confirmed disability accrual (CDA), relapse-associated worsening (RAW), progression independent of relapse activity (PIRA), and transition to secondary progressive (SP) MS, and ACES and RAM rates under each disease-modifying therapy (DMT) were estimated. RESULTS: Among 31 885 clinical events, 637 in 608 patients (493 [77.4%] female; mean [SD] age, 35.8 [10.7] years) were included. ACES accounted for 166 (26.1%) events and were more likely in patients receiving highly effective DMTs, those with longer disease duration (odds ratio [OR], 1.04; 95% CI, 1.01-1.07), or those presenting with fatigue (OR, 2.14; 95% CI, 1.15-3.96). ACES were associated with significant EDSS score increases, lower than those found for RAM. Before the index event, patients with ACES experienced significantly higher rates of relapse (relative rate [RR], 1.21; 95% CI, 1.01-1.46), CDA (hazard ratio [HR], 1.54; 95% CI, 1.13-2.11), and RAW (HR, 1.72; 95% CI, 1.20-2.45). Patients with ACES were at significantly greater risk of SP transition (HR, 2.58; 95% CI, 1.02-6.51). Although RAM rate decreased with DMTs according to their expected efficacy, ACES rate was stable across DMTs. CONCLUSIONS AND RELEVANCE: The findings in this study introduce the concept of ACES in MS, which accounted for one-fourth of clinical events identified as relapses.

Published
2024
Full Text
View/download PDF

31. The biological sample collection of the OFSEP French MS registry: An essential tool dedicated to researchers

Author

Brocard, Guillaume, primary, Casey, Romain, additional, Dufay, Nathalie, additional, Marignier, Romain, additional, Michel, Laure, additional, Hisbergues, Michael, additional, Ayrignac, Xavier, additional, Lehmann, Sylvain, additional, Thouvenot, Eric, additional, Gallot, Geraldine, additional, Collongues, Nicolas, additional, Herpe, Yves-Edouard, additional, Lebrun-Frenay, Christine, additional, Cotton, François, additional, De Sèze, Jérôme, additional, Guillemin, Francis, additional, Moreau, Thibault, additional, Pelletier, Jean, additional, Stankoff, Bruno, additional, Vukusic, Sandra, additional, Zephir, Hélène, additional, and Laplaud, David, additional

Published
2023
Full Text
View/download PDF

33. Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions

Author

Ayrignac, Xavier, Rigau, Valérie, Lhermitte, Benoit, Vincent, Thierry, de Champfleur, Nicolas Menjot, Carra-Dalliere, Clarisse, Charif, Mahmoud, Collongues, Nicolas, de Seze, Jérôme, Hebbadj, Sonia, Ahle, Guido, Oesterlé, Hélène, Cotton, François, Durand-Dubief, Françoise, Marignier, Romain, Vukusic, Sandra, Taithe, Frédéric, Cohen, Mikael, Guennoc, Anne-Marie, Kerbrat, Anne, Edan, Gilles, Carsin-Nicol, Béatrice, Allou, Thibaut, Sablot, Denis, Thouvenot, Eric, Ruet, Aurélie, Magy, Laurent, Boncoeur-Martel, Marie-Paule, Labauge, Pierre, and Kremer, Stéphane

Published
2019
Full Text
View/download PDF

34. Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults

Author

Cobo-Calvo, Alvaro, Sepúlveda, María, d’Indy, Hyacintha, Armangué, Thais, Ruiz, Anne, Maillart, Elisabeth, Papeix, Caroline, Audoin, Bertrand, Zephir, Helene, Biotti, Damien, Ciron, Jonathan, Durand-Dubief, Francoise, Collongues, Nicolas, Ayrignac, Xavier, Labauge, Pierre, Thouvenot, Eric, Montcuquet, Alexis, Deschamps, Romain, Solà-Valls, Nuria, Llufriu, Sara, Blanco, Yolanda, de Seze, Jerome, Vukusic, Sandra, Saiz, Albert, Marignier, Romain, The OFSEP Group, and The REEM Group

Published
2019
Full Text
View/download PDF

35. Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals

Author

Lehmann, Sylvain, Dumurgier, Julien, Ayrignac, Xavier, Marelli, Cecilia, Alcolea, Daniel, Ormaechea, Juan Fortea, Thouvenot, Eric, Delaby, Constance, Hirtz, Christophe, Vialaret, Jérôme, Ginestet, Nelly, Bouaziz-Amar, Elodie, Laplanche, Jean-Louis, Labauge, Pierre, Paquet, Claire, Lleo, Alberto, and Gabelle, Audrey

Published
2020
Full Text
View/download PDF

36. The Risetime of Nearby Type Ia Supernovae

Author

Riess, Adam G., Filippenko, Alexei V., Li, Weidong, Treffers, Richard R., Schmidt, Brian P., Qiu, Yulei, Hu, Jingyao, Armstrong, Mark, Faranda, Chuck, and Thouvenot, Eric

Subjects
Astrophysics
Abstract

We present calibrated photometric measurements of the earliest detections of nearby type Ia supernovae (SNe Ia). The set of ~30 new, unfiltered CCD observations delineate the early rise behavior of SNe Ia > 18 to 10 days before maximum. Using simple empirical models, we demonstrate the strong correlation between the risetime (i.e., the time between explosion and maximum), the post-rise light-curve shape, and the peak luminosity. Using a variety of light-curve shape methods, we find the risetime to B maximum for a SN Ia with Delta m15(B)=1.1 mag and peak M_V=-19.45 mag to be 19.5+/-0.2 days. We find that the peak brightness of SNe Ia is correlated with their risetime; SNe Ia which are 0.10 mag brighter at peak in the B-band require 0.80+/-0.05 days longer to reach maximum light. We determine the effects of several possible sources of systematic errors, but none of these significantly impacts the inferred risetime. Constraints on SN Ia progenitor systems and explosion models are derived from a comparison between the observed and theoretical predictions of the risetime., Comment: Submitted to the Astronomical Journal, 24 pages, 7 figures

Published
1999
Full Text
View/download PDF

37. Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study

Author

Cohen, Mikael, primary, Thomel-Rocchi, Océane, additional, Siva, Aksel, additional, Okuda, Darin T, additional, Karabudak, Rana, additional, Efendi, Hüsnü, additional, Terzi, Murat, additional, Carra-Dalliere, Clarisse, additional, Durand-Dubief, Francoise, additional, Thouvenot, Eric, additional, Ciron, Jonathan, additional, Zephir, Helene, additional, Bourre, Bertrand, additional, Casez, Olivier, additional, De Seze, Jérôme, additional, Moreau, Thibault, additional, Neau, Jean-Philippe, additional, Pelletier, Daniel, additional, Kantarci, Orhun, additional, Tutuncu, Melih, additional, Derache, Nathalie, additional, Bensa, Caroline, additional, Louapre, Celine, additional, Benoit, Jeanne, additional, Landes-Chateau, Cassandre, additional, and Lebrun-Frenay, Christine, additional

Published
2023
Full Text
View/download PDF

38. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS

Author

Jouvenot, Guillaume, Courbon, Guilhem, Lefort, Mathilde, Rollot, Fabien, Casey, Romain, Le Page, Emmanuelle, Michel, Laure, Edan, Gilles, de Seze, Jérome, Kremer, Laurent, Bigaut, Kevin, Vukusic, Sandra, Mathey, Guillaume, Ciron, Jonathan, Ruet, Aurélie, Maillart, Elisabeth, Labauge, Pierre, Zephir, Hélène, Papeix, Caroline, Defer, Gilles, Lebrun-Frenay, Christine, Moreau, Thibault, Laplaud, David Axel, Berger, Eric, Stankoff, Bruno, Clavelou, Pierre, Thouvenot, Eric, Heinzlef, Olivier, Pelletier, Jean, Al-Khedr, Abdullatif, Casez, Olivier, Bourre, Bertrand, Cabre, Philippe, Wahab, Abir, Magy, Laurent, Camdessanché, Jean-Philippe, Doghri, Ines, Moulin, Solène, Ben-Nasr, Haifa, Labeyrie, Céline, Hankiewicz, Karolina, Neau, Jean-Philippe, Pottier, Corinne, Nifle, Chantal, Collongues, Nicolas, and Kerbrat, Anne

Abstract

IMPORTANCE: A recent randomized clinical trial concluded that discontinuing medium-efficacy therapy might be a reasonable option for older patients with nonactive multiple sclerosis (MS), but there is a lack of data on discontinuing high-efficacy therapy (HET). In younger patients, the discontinuation of natalizumab and fingolimod is associated with a risk of rebound of disease activity. OBJECTIVE: To determine whether discontinuing HET in patients 50 years and older with nonactive MS is associated with an increased risk of relapse compared with continuing HET. DESIGN, SETTING, AND PARTICIPANTS: This observational cohort study used data from 38 referral centers from the French MS registry (Observatoire Français de la Sclérose en Plaques [OFSEP] database). Among 84704 patients in the database, data were extracted for 1857 patients 50 years and older with relapsing-remitting MS treated by HET and with no relapse or magnetic resonance imaging activity for at least 2 years. After verification of the medical records, 1620 patients were classified as having discontinued HET or having remained taking treatment and were matched 1:1 using a dynamic propensity score (including age, sex, disease phenotype, disability, treatment of interest, and time since last inflammatory activity). Patients were included from February 2008 to November 2021, with a mean (SD) follow-up of 5.1 (2.9) years. Data were extracted in June 2022. EXPOSURES: Natalizumab, fingolimod, rituximab, and ocrelizumab. MAIN OUTCOMES AND MEASURES: Time to first relapse. RESULTS: Of 1620 included patients, 1175 (72.5%) were female, and the mean (SD) age was 54.7 (4.8) years. Among the 1452 in the HET continuation group and 168 in the HET discontinuation group, 154 patients in each group were matched using propensity scores (mean [SD] age, 57.7 [5.5] years; mean [SD] delay since the last inflammatory activity, 5.6 [3.8] years; mean [SD] follow-up duration after propensity score matching, 2.5 [2.1] years). Time to first relapse was significantly reduced in the HET discontinuation group compared with the HET continuation group (hazard ratio, 4.1; 95% CI, 2.0-8.5; P &lt; .001) but differed between HETs, with a hazard ratio of 7.2 (95% CI, 2.1-24.5; P = .001) for natalizumab, 4.5 (95% CI, 1.3-15.5; P = .02) for fingolimod, and 1.1 (95% CI, 0.3-4.8; P = .85) for anti-CD20 therapy. CONCLUSION AND RELEVANCE: As in younger patients, in patients 50 years and older with nonactive MS, the risk of relapse increased significantly after stopping HETs that impact immune cell trafficking (natalizumab and fingolimod). There was no significant increase in risk after stopping HETs that deplete B-cells (anti-CD20 therapy). This result may inform decisions about stopping HETs in clinical practice.

Published
2024
Full Text
View/download PDF

39. Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis

Author

Benallegue, Nail, Rollot, Fabien, Wiertlewski, Sandrine, Casey, Romain, Debouverie, Marc, Kerbrat, Anne, De Seze, Jérôme, Ciron, Jonathan, Ruet, Aurelie, Labauge, Pierre, Maillart, Elisabeth, Zephir, Helene, Papeix, Caroline, Defer, Gilles, Lebrun-Frenay, Christine, Moreau, Thibault, Berger, Eric, Stankoff, Bruno, Clavelou, Pierre, Heinzlef, Olivier, Pelletier, Jean, Thouvenot, Eric, Al Khedr, Abdullatif, Bourre, Bertrand, Casez, Olivier, Cabre, Philippe, Wahab, Abir, Magy, Laurent, Vukusic, Sandra, and Laplaud, David-Axel

Abstract

IMPORTANCE: Moderately effective therapies (METs) have been the main treatment in pediatric-onset multiple sclerosis (POMS) for years. Despite the expanding use of highly effective therapies (HETs), treatment strategies for POMS still lack consensus. OBJECTIVE: To assess the real-world association of HET as an index treatment compared with MET with disease activity. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study conducted from January 1, 2010, to December 8, 2022, until the last recorded visit. The median follow-up was 5.8 years. A total of 36 French MS centers participated in the Observatoire Français de la Sclérose en Plaques (OFSEP) cohort. Of the total participants in OFSEP, only treatment-naive children with relapsing-remitting POMS who received a first HET or MET before adulthood and at least 1 follow-up clinical visit were included in the study. All eligible participants were included in the study, and none declined to participate. EXPOSURE: HET or MET at treatment initiation. MAIN OUTCOMES AND MEASURES: The primary outcome was the time to first relapse after treatment. Secondary outcomes were annualized relapse rate (ARR), magnetic resonance imaging (MRI) activity, time to Expanded Disability Status Scale (EDSS) progression, tertiary education attainment, and treatment safety/tolerability. An adapted statistical method was used to model the logarithm of event rate by penalized splines of time, allowing adjustment for effects of covariates that is sensitive to nonlinearity and interactions. RESULTS: Of the 3841 children (5.2% of 74 367 total participants in OFSEP), 530 patients (mean [SD] age, 16.0 [1.8] years; 364 female [68.7%]) were included in the study. In study patients, both treatment strategies were associated with a reduced risk of first relapse within the first 2 years. HET dampened disease activity with a 54% reduction in first relapse risk (adjusted hazard ratio [HR], 0.46; 95% CI, 0.31-0.67; P &lt; .001) sustained over 5 years, confirmed on MRI activity (adjusted odds ratio [OR], 0.34; 95% CI, 0.18-0.66; P = .001), and with a better tolerability pattern than MET. The risk of discontinuation at 2 years was 6 times higher with MET (HR, 5.97; 95% CI, 2.92-12.20). The primary reasons for treatment discontinuation were lack of efficacy and intolerance. Index treatment was not associated with EDSS progression or tertiary education attainment (adjusted OR, 0.51; 95% CI, 0.24-1.10; P = .09). CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that compared with MET, initial HET in POMS was associated with a reduction in the risk of first relapse with an optimal outcome within the first 2 years and was associated with a lower rate of treatment switching and a better midterm tolerance in children. These findings suggest prioritizing initial HET in POMS, although long-term safety studies are needed.

Published
2024
Full Text
View/download PDF

41. Cerebellar Superficial Siderosis in Cerebral Amyloid Angiopathy on 1.5T T2*-Weighted Imaging.

Author

Renard, Dimitri, Laurent-Chabalier, Sabine, Leonte, Adelina, Hackius, Marc, Parvu, Teodora, Wacongne, Anne, and Thouvenot, Eric

Subjects
CEREBRAL amyloid angiopathy
Abstract

Background: Cerebellar superficial siderosis (SS) has been recently reported to be present in about 10% of both hereditary and sporadic cerebral amyloid angiopathy (CAA) on 3T MRI using primarily susceptibility-weighted imaging. Objectives: Our aim was to assess cerebellar SS in sporadic CAA patients using 1.5T T2*-weighted MRI and to evaluate possible underlying mechanisms. Method: We retrospectively screened MRI scans of sporadic probable CAA patients initially presenting with intracerebral hemorrhage-, acute subarachnoid hemorrhage- or cortical SS-related symptoms between September 2009 and January 2022 registered in our stroke database. Patients with familial CAA were excluded. On 1.5T T2*-weighted MRI, cerebellar SS (including kappa statistics for interobserver agreement) was assessed together with typical CAA hemorrhagic features and with the presence of supratentorial macrobleed and cortical SS adjacent to the tentorium cerebelli (TC) and TC hemosiderosis. Results: We screened 151 patients and finally included 111 CAA patients (median age 77) with cerebellar SS observed in 6 (5%) patients. Cerebellar SS presence was associated with a higher number of supratentorial macrobleeds (median n = 3 vs. n = 1, p = 0.0012), presence of supratentorial macrobleed adjacent to the TC (p = 0.002), and TC hemosiderosis (p = 0.005). Conclusions: Cerebellar SS in CAA patients can be identified on 1.5T T2*-weighted imaging. Associated MRI characteristics suggest contamination from supratentorial macrobleeds. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

42. Understanding functional neurological disorders: From biological markers to pathophysiological models

Author

Conejero, Ismael, Thouvenot, Eric, Hingray, Coraline, Hubsch, Cécile, El-Hage, Wissam, Carle-Toulemonde, Guilhem, Rotge, Jean-Yves, Drapier, Sophie, Drapier, Dominique, Mouchabac, Stéphane, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut de Génomique Fonctionnelle - Montpellier GenomiX (IGF MGX), Institut de Génomique Fonctionnelle (IGF), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-BioCampus (BCM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Psychothérapique de Nancy [Laxou] (CPN), Fondation Ophtalmologique Adolphe de Rothschild [Paris], Clinique Psychiatrique Universitaire [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Université de Rennes (UR), Centre Hospitalier Guillaume Régnier [Rennes], Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), and None

Subjects
[SDV]Life Sciences [q-bio], Neurosciences, Neuroimaging, Trouble neurologique fonctionnel, Functional neurological disorders, Stress, Neuroimagerie, Neuroscience
Abstract

National audience; OBJECTIVES: Functional neurological disorders have witnessed intense research activity in the fields of structural and functional neuroimaging for more than twenty years. Thus, we propose a synthesis of recent research findings and etiological hypotheses that have been proposed so far. This work should help clinicians to better understand the nature of the mechanisms involved, but also help patients to increase their knowledge about the biological features underlying their functional symptoms. METHODS: We carried out a narrative review of international publications dealing with neuroimaging and biology of functional neurological disorders, from 1997 to 2023. RESULTS: Several brain networks underlie functional neurological symptoms. These networks play a role in the management of cognitive resources, in attentional control, emotion regulation, in agency and in the processing of interoceptive signals. The mechanisms of the stress response are also associated with the symptoms. The biopsychosocial model helps to better understand predisposing, precipitating, and perpetuating factors involved. The functional neurological phenotype results from the interaction between: i) a specific pre-existing vulnerability resulting from biological background and epigenetic modifications, and ii) exposure to stress factors, according to the stress-diathesis model. This interaction causes emotional disturbances including hypervigilance, lack of integration of sensations and affects, and emotional dysregulation. These characteristics in turn impact the cognitive, motor and affective control processes related with the functional neurological symptoms. CONCLUSIONS: A better knowledge of the biopsychosocial determinants of brain network dysfunctions is necessary. Understanding them would help developing targeted treatments, but is also critical for patients care.

Published
2023

46. Syndecan-1 as specific cerebrospinal fluid biomarker of multiple sclerosis

Author

Hinsinger, Geoffrey, primary, Du Trieu de Terdonck, Lucile, additional, Urbach, Serge, additional, Salvetat, Nicolas, additional, Rival, Manon, additional, Galoppin, Manon, additional, Ripoll, Chantal, additional, Cezar, Renaud, additional, Laurent-Chabalier, Sabine, additional, Demattei, Christophe, additional, Agherbi, Hanane, additional, Castelnovo, Giovanni, additional, Lehmann, Sylvain, additional, Rigau, Valerie, additional, Marin, Philippe, additional, and Thouvenot, Eric, additional

Published
2023
Full Text
View/download PDF

49. The radiologically isolated syndrome: revised diagnostic criteria

Author

Lebrun-Frénay, Christine, primary, Okuda, Darin T, additional, Siva, Aksel, additional, Landes-Chateau, Cassandre, additional, Azevedo, Christina J, additional, Mondot, Lydiane, additional, Carra-Dallière, Clarisse, additional, Zephir, Helene, additional, Louapre, Celine, additional, Durand-Dubief, Françoise, additional, Le Page, Emmanuelle, additional, Bensa, Caroline, additional, Ruet, Aurélie, additional, Ciron, Jonathan, additional, Laplaud, David A, additional, Casez, Olivier, additional, Mathey, Guillaume, additional, de Seze, Jerome, additional, Zeydan, Burcu, additional, Makhani, Naila, additional, Tutuncu, Melih, additional, Levraut, Michael, additional, Cohen, Mikael, additional, Thouvenot, Eric, additional, Pelletier, Daniel, additional, and Kantarci, Orhun H, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results